ERBB4 and neuroblastoma: Developed resistance to ALK and pan-TRK inhibitor entrectinib in ALKF1174L NB xenografts was associated with increased TRKB or IGF1R activation [251], and resistance to lorlatinib in NB cells was accompanied by EGFR and HER4 overactivation [252].